Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00058357 · ClinicalTrials.gov registry record · Phase 3

Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery

A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
30
Enrollment target

NCT00058357: Completed Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.

NCT00058357 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00058357, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
30 participants
Enrollment target

Study Summary

RATIONALE: A lidocaine patch may be effective in relieving numbness, tingling, and other symptoms of neuropathy. It is not yet known whether a lidocaine patch is effective in treating neuropathy in patients who have undergone surgery for cancer. PURPOSE: This randomized phase III trial is studying lidocaine patch to see how well it works compared to a placebo patch in relieving numbness, tingling, and other symptoms of neuropathy in patients who have undergone surgery for cancer.

Interventions

  • OTHER placebo
  • DRUG lidocaine

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2004-05
Est. Completion 2007-07
Phase Phase 3

What the finished NCT00058357 record still lists

NCT00058357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00058357 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00058357 about?

NCT00058357 is a clinical study titled "Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery". RATIONALE: A lidocaine patch may be effective in relieving numbness, tingling, and other symptoms of neuropathy. It is not yet known whether a lidocaine patch is effective in treating neuropathy in patients who have undergone surgery for cancer. PURPOSE: This randomized phase III trial is studying ...

What is the current status of trial NCT00058357?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2004-05. Estimated completion is 2007-07.

What interventions are being tested in trial NCT00058357?

The interventions under investigation include: placebo (OTHER), lidocaine (DRUG).

Who is sponsoring clinical trial NCT00058357?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00058357's enrollment target sits among peer trials

30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00058357, the US trial registry maintained by the National Library of Medicine. NCT00058357 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.